Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial-Reference-Cited by-同舟云学术

Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial

Published:2023-06 Issue:6 Volume:8 Page:511-522
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Loomba Rohit,Abdelmalek Manal F,Armstrong Matthew J,Jara Maximilian,Kjær Mette Skalshøi,Krarup Niels,Lawitz Eric,Ratziu Vlad,Sanyal Arun J,Schattenberg Jörn M,Newsome Philip N

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

National Center for Advancing Translational Sciences

National Institute for Health and Care Research

Novo Nordisk

Birmingham Biomedical Research Centre

National Heart, Lung, and Blood Institute

National Institute on Alcohol Abuse and Alcoholism

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference33 articles.

1. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis;Taylor;Gastroenterology,2020

2. Prospective study of outcomes in adults with nonalcoholic fatty liver disease;Sanyal;N Engl J Med,2021

3. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis;Mantovani;Lancet Gastroenterol Hepatol,2021

4. Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: a systematic review and meta-analysis;Ng;Clin Gastroenterol Hepatol,2022

5. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease;Estes;Hepatology,2018

Cited by 156 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diabetes as a risk factor for MASH progression;Diabetes Research and Clinical Practice;2024-11

3. Targeting mitochondrial homeostasis in the treatment of non-alcoholic fatty liver disease: a review;Frontiers in Pharmacology;2024-09-03

4. Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Steatotic Liver Disease in Patients With Type 2 Diabetes Mellitus: Growing Evidence But Not Yet There;Gastroenterology;2024-09

5. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD);Journal of Hepatology;2024-09